Information processing system and information processing method

Abstract

To provide an information processing system and an information processing method capable of outputting DNA / RNA data for synthesis having good quality in order to synthesize a mutated peptide.SOLUTION: An information processing system 1 includes a first diagnosis part 11 for diagnosing the quality of first fragmented DNA / RNA data outputted by a first sequencer 21 to a sample extracted from a tissue of a patient, and determining first diagnostic data representing a diagnostic result, a second diagnosis part 12 for diagnosing the quality of second fragmented DNA / RNA data outputted by a second sequencer 22, and determining second diagnostic data representing a diagnostic result, and an output part 13 for outputting DNA / RNA data for synthesis from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data on the basis of the first diagnostic data and the second diagnostic data.SELECTED DRAWING: Figure 2

Description

[Technical Field]

[0001] The present invention relates to an information processing system and an information processing method. [Background technology]

[0002] Traditionally, existing pharmaceuticals have been manufactured in advance, stored in pharmacies, and prescribed to patients according to a doctor's prescription. In recent years, however, medicines tailored to the patient's constitution and the characteristics of their illness (hereinafter referred to as personalized medicine) have begun to be administered to patients.

[0003] In previous cancer treatments, treatments and drugs were selected according to the type of cancer, such as lung cancer, colon cancer, or breast cancer. However, in the 2000s, progress was made in understanding the molecules (proteins) that cause cancer and the genes that underlie them, making it possible to use "molecularly targeted drugs" that act on these molecules and genes. Further developments in molecularly targeted drugs have also led to the development of treatments that target individual patient molecules and genes. Treatment tailored to each individual, based not only on the type of cancer but also on the characteristics of the cancer, such as gene mutations, is called "personalized treatment." Traditionally, "personalized treatment" based on cancer genetic information has primarily been carried out based on "cancer gene testing," which examines a small number of genes, and "cancer gene panel testing," which examines a large number of genes simultaneously.

[0004] In recent years, there has been progress in cancer immunotherapy (hereafter referred to as cancer vaccine therapy), which "uses the natural immune power of the human body to attack and eliminate cancer cells." One type of cancer vaccine therapy is known as a "peptide vaccine." Peptide vaccines contain antigens that serve as markers for cancer. When these antigens are injected directly into the body, the human body's natural immune system detects an abnormality and targets and attacks the antigens that serve as markers for cancer, thereby killing the cancer cells.

[0005] In recent years, we have entered an era where all genetic mutations in each patient's cancer can be easily identified, and the importance of newly generated "peptides" resulting from these genetic mutations has been highlighted in cancer immunotherapy. These peptides are mutant peptides known as "neoantigens." It has become clear that when these peptides are displayed on the surface of cancer cells via human leukocyte antigens (HLA), which are not present on the surface of normal cells, cytotoxic T lymphocytes (CTLs) recognize them as enemies and are able to kill the cancer cells. Currently, clinical trials are being conducted in Europe and the United States to verify whether personalized cancer vaccine therapy using "neoantigens" is effective as a cancer treatment or recurrence prevention method. Patent Document 1 also discloses a method for identifying polypeptide fragments that are immunogenic in specific human subjects, and a method for preparing personalized pharmaceutical compositions containing the polypeptide fragments. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Special Publication No. 2020-510698 Summary of the Invention [Problem to be solved by the invention]

[0007] Because the types and numbers of mutated peptides known as "neoantigens" vary from patient to patient, it is necessary to produce a peptide vaccine from the genetic mutations in the patient's cancer tissue individually for each patient. The peptide vaccine must be delivered to the patient before the patient's disease progresses, but because this production is made to order, if there is an error in one of the multiple steps, that step must be repeated, resulting in a delay in delivery to the patient.

[0008] In the peptide vaccine production process, fragmented DNA (DeoxyriboNucleic Acid) data is output after pre-analysis and analytical processes before the vaccine recipe is created. The pre-analysis process includes, for example, specimen collection, formalin fixation, preparation of a pathological specimen, confirmation of tumor cell ratio, determination of the pathological specimen for genetic testing, and nucleic acid extraction from the confirmed specimen. The analytical process includes, for example, library preparation, replication by PCR (Polymerase Chain Reaction), sequencing, and data output. The sequencer output data is a collection of numerous fragments of DNA / RNA data, affected by the fragmentation performed in the library preparation.

[0009] The output data from sequencers is subject to inconsistent results due to the influence of pre-analysis and analytical processes. It is particularly affected by the quality of the input DNA sample, variations in the PCR process, and sequencing accuracy. Typically, the quality of the output data is ensured by validation, internal quality control, and external quality control, based on quality control standards established for each process. However, poor quality may be discovered at the end of the process, and if the data needs to be redone, this can delay vaccine production and delivery to patients.

[0010] In addition to cancer vaccines, there is also the possibility of treating autoimmune diseases with similar neoantigens, and similar issues exist in personalized medicine for autoimmune diseases.

[0011] The present invention has been made in consideration of the above-mentioned problems, and aims to provide an information processing system and an information processing method that make it possible to suppress delays in the production of vaccines for personalized medicine. [Means for solving the problem]

[0012] An information processing system according to a first aspect of the present invention is an information processing system that outputs DNA / RNA data for synthesis used to synthesize mutant peptides derived from cancer gene mutations, and includes a first diagnostic unit that diagnoses the quality of the sequence of first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient using the quality data output from the first sequencer and determines at least one piece of first diagnostic data representing a diagnostic result, a second diagnostic unit that diagnoses the quality of the sequence of second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient using the quality data output from the second sequencer and determines at least one piece of second diagnostic data representing a diagnostic result, and an output unit that outputs the DNA / RNA data for synthesis from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data.

[0013] This configuration increases the likelihood that high-quality DNA / RNA synthesis data will be output for synthesizing mutant peptides, and reduces the need for rework due to deterioration in the quality of the DNA / RNA synthesis data, thereby reducing delays in the production of personalized cancer vaccines.

[0014] An information processing system according to a second aspect of the present invention is an information processing system according to the first aspect, wherein the first diagnostic unit diagnoses the quality of the sequence of the first fragmented DNA / RNA data using quality data output from the first sequencer as well as quality information of a pre-analysis process performed before the sequencing of the first sequencer to determine the first diagnostic data, and the second diagnostic unit diagnoses the quality of the sequence of the second fragmented DNA / RNA data using quality data output from the second sequencer as well as quality information of a pre-analysis process performed before the sequencing of the second sequencer to determine the second diagnostic data.

[0015] An information processing system according to a third aspect of the present invention is an information processing system according to the first or second aspect, wherein the output unit may switch between the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data and output the switched data as the DNA / RNA data for synthesis.

[0016] An information processing system according to a fourth aspect of the present invention is an information processing system according to the first or second aspect, wherein the output unit may combine a portion of the first fragmented DNA / RNA data and a portion of the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and output the combined data as the DNA / RNA data for synthesis.

[0017] An information processing system according to a fifth aspect of the present invention is an information processing system that outputs DNA / RNA data for synthesis used to synthesize mutant peptides derived from cancer gene mutations, and is equipped with an output unit that combines first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient and second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient, and outputs the combined data as DNA / RNA data for synthesis.

[0018] An information processing system according to a sixth aspect of the present invention is the information processing system according to the fifth aspect, wherein the output unit, when outputting the DNA / RNA data for synthesis, may output diagnostic data including the priority of the mutant peptides together with the DNA / RNA data for synthesis.

[0019] An information processing system according to a seventh aspect of the present invention is an information processing system that outputs DNA / RNA data for synthesis to synthesize mutant peptides derived from cancer gene mutations, and is equipped with an output unit that determines the DNA / RNA data for synthesis by taking a majority vote of the bases in corresponding orders in first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient, second fragmented DNA / RNA data output by a second sequencer for the sample extracted from the tissue of the target patient, and third fragmented DNA / RNA data output by a third sequencer for the sample extracted from the tissue of the target patient to determine the order of the bases in each.

[0020] An information processing method according to an eighth aspect of the present invention is an information processing method for outputting DNA / RNA data for synthesis to synthesize mutant peptides derived from cancer gene mutations, and includes the steps of: diagnosing the quality of the sequence of first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient using the quality data output from the first sequencer, and determining at least one piece of first diagnostic data representing the diagnostic result; diagnosing the quality of the sequence of second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient using the quality data output from the second sequencer, and determining at least one piece of second diagnostic data representing the diagnostic result; and outputting the DNA / RNA data for synthesis from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data.

[0021] An information processing method according to a ninth aspect of the present invention is an information processing method for outputting DNA / RNA data for synthesis for synthesizing a mutant peptide derived from a cancer gene mutation, and includes a step of combining first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient and second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient, and outputting the combined data as DNA / RNA data for synthesis.

[0022] An information processing method according to a tenth aspect of the present invention is an information processing method for outputting DNA / RNA data for synthesis used to synthesize mutant peptides derived from cancer gene mutations, and includes a step of determining the DNA / RNA data for synthesis by taking a majority vote of the bases in corresponding orders in first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient, second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the target patient, and third fragmented DNA / RNA data output by a third sequencer for the sample extracted from the tissue of the target patient, to determine the order of the bases in each of the first fragmented DNA / RNA data. [Effects of the Invention]

[0023] According to one aspect of the present invention, the likelihood of outputting high-quality DNA / RNA synthesis data for synthesizing mutant peptides is improved, and the need for rework due to deterioration in the quality of DNA / RNA synthesis data is reduced, thereby reducing delays in the production of personalized cancer vaccines. [Brief explanation of the drawings]

[0024] [Figure 1] FIG. 1 is a schematic diagram showing an example of a manufacturing process for a personalized cancer vaccine. [Figure 2] 1 is a schematic block diagram of an information processing system according to a first embodiment. [Figure 3A] FIG. 3 is a schematic diagram illustrating processing by an output unit according to the first embodiment. [Figure 3B] FIG. 10 is a schematic diagram illustrating processing by an output unit according to a first modified example of the first embodiment. [Figure 4] FIG. 10 is a schematic block diagram of an information processing system according to a second modification of the first embodiment. [Figure 5] FIG. 10 is a schematic block diagram of an information processing system according to a second embodiment. [Figure 6] FIG. 10 is a schematic block diagram of an information processing system according to a third embodiment. DETAILED DESCRIPTION OF THE INVENTION

[0025] Hereinafter, each embodiment will be described with reference to the drawings. However, unnecessary detailed description may be omitted. For example, detailed description of well-known matters or redundant description of substantially the same configuration may be omitted. This is to avoid unnecessary redundancy in the following description and to facilitate understanding by those skilled in the art.

[0026] FIG. 1 is a schematic diagram showing an example of the manufacturing process for a personalized cancer vaccine.

[0027] (Step S10) First, a doctor performs surgery to remove cancer tissue from a patient, and then extracts a DNA / RNA sample from the cancer tissue or tissue specimen.

[0028] (Step S20) Next, the DNA / RNA sample is transported and stored, for example, at a vendor, which has a next-generation sequencer.

[0029] (Step S30) Next, the genome of the DNA / RNA sample is read by a next-generation sequencer, and DNA / RNA data for synthesis is output, which is used to synthesize mutant peptides (i.e., neoantigens) derived from cancer gene mutations.

[0030] (Step S40) Next, a recipe for a personalized cancer vaccine is created from the DNA / RNA data for synthesis.

[0031] (Step S50) Next, a personalized cancer vaccine is produced from the created recipe.

[0032] (Step S60) Next, the manufactured personalized cancer vaccine is transported and stored at the hospital.

[0033] (Step S70) The personalized cancer vaccine is injected into the target patient.

[0034] If the quality of the DNA / RNA data to be synthesized deteriorates, it will be necessary to start over from transporting the sample in step S20, which will result in a delay in the production of the personalized cancer vaccine. To address this problem, the present embodiment provides an information processing system and information processing method for suppressing deterioration in the quality of the DNA / RNA data to be synthesized.

[0035] <First embodiment: output switching> In this embodiment, the sequencers are parallelized, and output data is integrated based on a diagnostic function that diagnoses operational and / or output quality data, including quality information for each pre-analysis process. Here, the quality data includes at least one of the following: depth of coverage (target region), uniformity of coverage (target region), GC bias, Ti / Tv ratio (Transition / Transversion ratio), base call quality scores, mapping quality, duplicate read success rate and removal of duplicate reads, first base read success rate, signal intensity decay, and DNA interstrand bias.

[0036] When collecting samples, it is preferable to use FFPE samples, and the warm ischemia time (from cessation of blood flow to extraction) and cold ischemia time (from extraction to fixation) are important.

[0037] Regarding the quality standard of the extracted nucleic acid, the ΔCt value (ΔΔCq), DIN value, Q-value, DV200, etc. may be used as the quality of the nucleic acid (mainly evaluating the degree of fragmentation).

[0038] Regarding library quality criteria, appropriate quality checks can be performed after library preparation, and indicators can be set in advance to determine whether the library is suitable for sequence analysis. These indicators can include DNA quantity and fragment size.

[0039] Fig. 2 is a schematic block diagram of an information processing system according to the first embodiment. As shown in Fig. 2, the information processing system 1 outputs DNA / RNA data for synthesis used to synthesize mutant peptides derived from cancer gene mutations, and includes a processor 10. The processor 10 loads a program into a memory (not shown) and executes a series of instructions included in the program, thereby functioning as a first diagnostic unit 11, a second diagnostic unit 12, and an output unit 13.

[0040] The first sequencer 21 is, for example, a next-generation sequencer that performs genome sequencing on a sample extracted from a cancer tissue of a subject patient to generate first fragmented DNA / RNA data and quality data indicating the quality of the genome sequence. The first sequencer 21 may have an HLA typing function.

[0041] Similarly, the second sequencer 22 is, for example, a next-generation sequencer, which performs genome sequencing on a sample extracted from the cancer tissue of the target patient and generates second fragmented DNA / RNA data and quality data indicating the quality of the genome sequence.

[0042] The first diagnostic unit 11 acquires the first fragmented DNA / RNA data and quality data from the first sequencer 21. The first diagnostic unit 11 diagnoses the quality of the sequence of the first fragmented DNA / RNA data output by the first sequencer for a sample extracted from the tissue of a target patient using the quality data output from the first sequencer, and determines at least one piece of first diagnostic data representing the diagnostic result.

[0043] The second diagnostic unit 12 acquires second fragmented DNA / RNA data and quality data from the second sequencer 22. The second diagnostic unit 12 diagnoses the quality of the sequence of the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the second sequencer, and determines at least one piece of second diagnostic data representing the diagnostic result.

[0044] The output unit 13 acquires the first fragmented DNA / RNA data from the first sequencer 21, acquires the second fragmented DNA / RNA data from the second sequencer 22, acquires the first diagnostic data from the first diagnostic unit 11, and acquires the second diagnostic data from the second diagnostic unit 12. The output unit 13 outputs the DNA / RNA data to be synthesized from the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data.

[0045] This configuration increases the likelihood that high-quality DNA / RNA synthesis data will be output for synthesizing mutant peptides, and reduces the need for rework due to deterioration in the quality of the DNA / RNA synthesis data, thereby reducing delays in the production of personalized cancer vaccines.

[0046] 3A is a schematic diagram showing the processing of the output unit according to the first embodiment. In the first embodiment, as shown in FIG. 3A, the output unit 13 switches between the first fragmented DNA / RNA data and the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and outputs the switched data as the DNA / RNA data to be synthesized. More specifically, the output unit 13 determines whether the first fragmented DNA / RNA data or the second fragmented DNA / RNA data is more appropriate based on the first diagnostic data and the second diagnostic data, and switches the output accordingly.

[0047] Specifically, for example, the output unit 13 may output only fragmented DNA / RNA data having more excellent indices than a set threshold among the multiple indices set for the diagnostic data. With this configuration, fragmented DNA / RNA data having many excellent indices is output for synthesizing mutant peptides, thereby reducing the need for rework due to deterioration in the quality of the DNA / RNA data to be synthesized, thereby suppressing delays in the production of personalized cancer vaccines.

[0048] <Modification 1 of the First Embodiment: Output Mixing> 3B is a schematic diagram showing processing by the output unit according to Modification 1 of the first embodiment. As shown in FIG. 3B, the output unit 13 may combine a part of the first fragmented DNA / RNA data and a part of the second fragmented DNA / RNA data based on the first diagnostic data and the second diagnostic data, and output the result as the DNA / RNA data to be synthesized.

[0049] Specifically, for example, when there is an index for each piece of fragmented DNA / RNA data, the output unit 13c may output a predetermined number of pieces of fragmented DNA / RNA data in descending order of the index.

[0050] Alternatively, the output unit 13c may, for example, analyze the frequency of fragmented data contained in the output data of both the first sequencer 21 and the second sequencer 22 (i.e., the first fragmented DNA / RNA data, the second fragmented DNA / RNA data), and output the cross-sectional data in order of frequency.

[0051] <Modification 2 of the First Embodiment> Fig. 4 is a schematic block diagram of an information processing system according to Modification 2 of the first embodiment. The information processing system 1b in Fig. 4 is different from the information processing system 1 in Fig. 2 in that the processing of the processor 10b is different, the first diagnostic unit 11 is changed to a first diagnostic unit 11b, and the second diagnostic unit 12 is changed to a second diagnostic unit 12b.

[0052] The first diagnostic unit 11b acquires an operation log including quality information of the pre-analysis process. The first diagnostic unit diagnoses the quality of the sequence of the first fragmented DNA / RNA data using the quality information of the pre-analysis process performed before the sequencing of the first sequencer 21 in addition to the quality data output from the first sequencer 21, and determines first diagnostic data. Specifically, for example, the first diagnostic unit 11b may diagnose that the quality is good if the quality data meets a first criterion and the quality information meets a second criterion, and may otherwise determine that the quality is poor, and determine first diagnostic data representing the diagnostic result.

[0053] Similarly, the second diagnostic unit 12b acquires an operation log including quality information of the pre-analysis process. The second diagnostic unit 12b diagnoses the sequence quality of the second fragmented DNA / RNA data using the quality information of the pre-analysis process performed before the sequencing of the second sequencer 22 in addition to the quality data output from the second sequencer 22, diagnoses the sequence quality of the second fragmented DNA / RNA data, and determines the second diagnostic data. Specifically, for example, if the quality data meets a first criterion and the quality information meets a second criterion, the second diagnostic unit 12b may diagnose the quality as good, and otherwise determine the quality as poor, and determine first diagnostic data representing the diagnostic result.

[0054] <Modification 3 of the First Embodiment> The output unit 13 may filter the double output data (the first and second fragmented DNA / RNA data) based on the first and second diagnostic data to limit the amount of DNA / RNA data to be synthesized. This filter may use at least one or more statistical values ​​such as number limit, magnitude of diagnostic data value for each read, and overlapping reads.

[0055] This configuration increases the likelihood that high-quality DNA / RNA synthesis data will be output for synthesizing mutant peptides, and reduces the need for rework due to deterioration in the quality of the DNA / RNA synthesis data, thereby reducing delays in the production of personalized cancer vaccines.

[0056] <Second embodiment: output coupling> 5 is a schematic block diagram of an information processing system according to a second embodiment. As shown in FIG. 5, the information processing system 1c includes a processor 10c. The processor 10c loads a program into a memory (not shown) and executes a series of instructions included in the program, thereby functioning as an output unit 13c. The output unit 13c combines the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the subject patient and the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient, and outputs the combined data as DNA / RNA data for synthesis.

[0057] Specifically, for example, when multiple indicators of the diagnostic data all exceed a threshold, the output unit 13c may combine both sets of data and output them as doubled data.

[0058] Alternatively, the output unit 13c may compare both sets of output data, and if the difference is small, combine both sets of data and output them as doubled data.

[0059] Furthermore, when outputting the DNA / RNA data for synthesis, the output unit 13c may output diagnostic data including the priority of the mutant peptides (neoantigens) together with the DNA / RNA data for synthesis. The priority may be determined based on the quality information and / or the quality data, and the higher the quality, the higher the priority may be set. With this configuration, high-quality DNA / RNA data for synthesis is preferentially used to synthesize mutant peptides, thereby reducing the need for rework due to deterioration in the quality of the DNA / RNA data for synthesis, and thus reducing delays in the production of personalized cancer vaccines.

[0060] Although the first and second embodiments are described assuming that the number of parallel connections is two, the number of parallel connections may be three or more, and may be determined by the amount of sample collected during surgery.

[0061] <Third embodiment: Majority vote> Fig. 6 is a schematic block diagram of an information processing system according to a third embodiment. As shown in Fig. 6, the information processing system 1d includes a processor 10d. The processor 10d functions as an output unit 13d by loading a program into a memory (not shown) and executing a series of instructions included in the program.

[0062] The output unit 13d acquires the first fragmented DNA / RNA data from the first sequencer 21. The output unit 13d also acquires the second fragmented DNA / RNA data from the second sequencer 22. The output unit 13d also acquires the third fragmented DNA / RNA data from the third sequencer 23.

[0063] The output unit 13d determines the DNA / RNA data to be synthesized by determining the order of bases in the corresponding orders of the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the target patient, the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the target patient, and the third fragmented DNA / RNA data output by the third sequencer for the sample extracted from the tissue of the target patient, by majority voting.

[0064] This configuration improves the accuracy of the DNA / RNA synthesis data used to synthesize mutant peptides, thereby reducing delays in the production of personalized cancer vaccines.

[0065] In addition to cancer vaccines, similar neoantigens may be used to treat autoimmune diseases, and similar embodiments can be used in personalized medicine for autoimmune diseases.

[0066] At least a part of the information processing system 1 described in the above embodiment may be configured with hardware or software. When configured with software, a program that realizes at least a part of the functions of the information processing system 1 may be stored in a computer-readable recording medium and read and executed by a computer. The recording medium is not limited to removable media such as magnetic disks and optical disks, but may also be fixed recording media such as hard disk drives and memories.

[0067] In addition, a program that realizes at least some of the functions of the information processing system 1 may be distributed via a communication line (including wireless communication) such as the Internet. Furthermore, the program may be encrypted, modulated, or compressed and distributed via a wired line or wireless line such as the Internet, or stored on a recording medium.

[0068] Furthermore, the information processing system 1 may be operated by one or more information devices. When multiple information devices are used, one of the devices may be a computer, and the computer may execute a predetermined program to realize the functions of at least one means of the information processing system 1.

[0069] In the method invention, all processes (steps) may be realized by automatic control using a computer. Alternatively, each process may be performed by a computer, with progress control between processes being performed manually. Furthermore, at least some of the processes may be performed manually.

[0070] As described above, the present invention is not limited to the above-described embodiments, and the components can be modified and embodied in practice without departing from the spirit of the invention. Furthermore, various inventions can be formed by appropriately combining multiple components disclosed in the above-described embodiments. For example, some components may be omitted from all the components shown in the embodiments. Furthermore, components from different embodiments may be appropriately combined. [Explanation of symbols]

[0071] 1, 1b, 1c, 1d Information Processing Systems 10, 10b, 10c, and 10d processors 11, 11b First diagnostic section 12, 12b Second diagnostic section 13, 13c, 13d Output section 21 First sequencer 22 Second sequencer 23 Third sequencer

Claims

1. An information processing system that outputs DNA / RNA data for synthesis used to synthesize mutant peptides derived from cancer gene mutations, a first diagnostic unit that diagnoses the quality of the sequence of the first fragmented DNA / RNA data output by the first sequencer for a sample extracted from the tissue of a target patient using the quality data output from the first sequencer, and determines at least one first diagnostic data item representing the diagnostic result; a second diagnostic unit that diagnoses the sequence quality of the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the second sequencer, and determines at least one second diagnostic data representing the diagnostic result; an output unit that combines the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the subject patient and the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient based on the first diagnostic data and the second diagnostic data, and outputs the combined data as DNA / RNA data for synthesis; An information processing system comprising:

2. When outputting the DNA / RNA data for synthesis, the output unit outputs diagnostic data including the priority order of the mutant peptides together with the DNA / RNA data for synthesis. The information processing system according to claim 1 .

3. An information processing system that outputs DNA / RNA data for synthesis for synthesizing a mutant peptide derived from a cancer gene mutation, an output unit that determines the order of bases to be synthesized by taking a majority vote between the bases in the corresponding orders of the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the target patient, the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the target patient, and the third fragmented DNA / RNA data output by the third sequencer for the sample extracted from the tissue of the target patient, An information processing system comprising:

4. 1. An information processing method for outputting DNA / RNA data for synthesis for synthesizing a mutant peptide derived from a cancer gene mutation, comprising: a step of diagnosing the quality of the sequence of the first fragmented DNA / RNA data output by the first sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the first sequencer, and determining at least one first diagnostic data representing the diagnostic result; a step of diagnosing the quality of the sequence of the second fragmented DNA / RNA data output by the second sequencer for the sample extracted from the tissue of the subject patient using the quality data output from the second sequencer, and determining at least one second diagnostic data representing the diagnostic result; a step of combining, based on the first diagnostic data and the second diagnostic data, first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a subject patient and second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of the subject patient, and outputting the combined data as DNA / RNA data for synthesis; An information processing method comprising:

5. 1. An information processing method for outputting DNA / RNA data for synthesis used to synthesize a mutant peptide derived from a cancer gene mutation, comprising: A procedure for determining DNA / RNA data to be synthesized by determining the order of bases by majority voting between the corresponding orders of bases in first fragmented DNA / RNA data output by a first sequencer for a sample extracted from the tissue of a target patient, second fragmented DNA / RNA data output by a second sequencer for a sample extracted from the tissue of said target patient, and third fragmented DNA / RNA data output by a third sequencer for a sample extracted from the tissue of said target patient. An information processing method comprising:

Images